WAKAMOTO PHARMACEUTICAL CO.,LTD.

4512・Standard Market・Pharmaceuticals

Official website

WAKAMOTO PHARMACEUTICAL CO.,LTD.

4512・Standard Market・Pharmaceuticals

Official website

WAKAMOTO PHARMACEUTICAL CO.,LTD.4512

Reference Indicators

Market Cap

94¥100M

P/E (Forecast)

40.9x

P/B

0.8x

Dividend Yield (Forecast)

1.29%

ROE

1.9%

EV/EBITDA

11.2x

Financial Summary

Unit: ¥M

Item	2022Mar 2022	2023Mar 2023	2024Mar 2024	2025Mar 2025	2026Mar 2026
Net Sales	8,383	8,660	7,738	7,789	9,906
Cost of Sales	4,027	4,552	4,138	4,166	5,176
Gross Profit	4,355	4,108	3,599	3,622	4,730
SG&A Expenses	4,369	3,966	3,795	4,080	4,474
Operating Income	-13	141	-195	-457	255
Non-operating Income	105	118	70	64	69
Non-operating Expenses	19	17	36	15	68
Ordinary Income	72	242	-161	-409	256
Extraordinary Income	212	—	366	419	—
Extraordinary Losses	0	31	45	3	—
Pre-tax Income	284	211	158	7	256
Income Taxes	46	73	49	-56	29
Net Income	238	138	108	64	227
EBITDA	456	587	216	-27	698
Gross Margin	52.0%	47.4%	46.5%	46.5%	47.7%
Operating Margin	-0.2%	1.6%	-2.5%	-5.9%	2.6%
ROA	1.6%	0.9%	0.7%	0.4%	1.4%
ROE	2.1%	1.2%	0.9%	0.6%	1.9%

Segment Performance

Unit: ¥M

2026

Segment	Net Sales	Operating Income	Operating Margin
医薬事業	4,762	-674	-14.2%
ヘルスケア事業	2,542	367	14.4%
グローバル事業	2,410	493	20.5%
不動産賃貸業	192	68	35.4%